



OFFICE OF THE DIRECTOR

Kate Brown, Governor

Oregon
Health
Authority

500 Summer St NE E20

Salem OR 97301

Voice: 503-947-2340

Fax: 503-947-2341

www.Oregon.Gov/OHA

www.health.oregon.gov

OFFICIAL WEBSITE NOTICE

Posting Date: July 30, 2019

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Salem, Oregon on Thursday, July 25, 2019. The Committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staffⁱ and all public comment offered,ⁱⁱ while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

Drug Use Review (DUR) Recommendations:

Opioid/Sedative Retrospective DUR Proposal

The Committee approved the retrospective DUR proposal, developed in response to the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act, which must be in place by October 1, 2019. Letters will be sent weekly to prescribers notifying them if their fee-for service patients fill prescriptions for a combination of opioid and sedative medications when the member has three or more unique prescribers of opioid and sedative therapy, or when there is a prior history of opioid or sedative poisoning. Staff will coordinate and collaborate with the CCOs to meet the requirement for their members.

Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:

Short-acting Beta Agonist Literature Scan

The Committee recommended making no changes to the PMPDP based on clinical evidence. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

Antidepressant Class Update and New Drug Evaluation (NDE)

The Committee recommended making no changes to the PMPDP based on the clinical evidence. Based on the safety concerns with brexanolone and esketamine, the Committee recommended implementing the proposed PA criteria after amending the esketamine safety edit to include a question about history of substance abuse. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP. The Committee also referred brexanolone and esketamine to the Mental Health Clinical Advisory Group (MHCAG) to review these two agents for their respective indications. Subsequent MHCAG recommendations will be taken under advisement by the Pharmacy & Therapeutics Committee.

Hereditary Transthyretin Mediated Amyloidosis (hATTR) NDE

The Committee recommended adding the drugs for hATTR class to the PMPDP and to designate inotersen and patisiran as non-preferred medications. The Committee also recommended implementing the proposed clinical PA criteria for patisiran and inotersen to ensure appropriate utilization, after amending to require baseline disease severity and to document genotype.

Atopic Dermatitis Class Update

The Committee recommended removing dupilumab from the atopic dermatitis and topical antipsoriatic PA criteria and to implement the dedicated criteria for dupilumab for moderate-to-severe asthma and atopic dermatitis after amending to: reflect the FDA approved ages for AD; reorder the questions to assess the prescribing practitioner at the beginning of the PA review; and add renewal criteria. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

Narcolepsy Agents Drug Effectiveness Review Project (DERP) Summary and NDE

The Committee recommended adding solriamfetol as a voluntary non-preferred product to the Other Stimulants class, to designate sodium oxybate as non-preferred based upon the current review of efficacy and safety data and to implement the proposed safety edit for solriamfetol after amending to require a trial and failure of first-line therapies (e.g., methylphenidate). The Committee also recommended updating the safety edit for modafinil/armodafinil to include assessment of first-line therapy in patients with obstructive sleep apnea and alternative options for treatment in children.

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 7 days from the date this notice is posted on the web site.



Patrick M. Allen
Director

July 30, 2019
Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. 2019 OR law, HB 2692

ⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2019_07_25/finals/2019_07_25_PnT_Complete.pdf

ⁱⁱ <https://www.oregon.gov/OHA/HSD/OHP/Pages/PT-Committee.aspx>